BHK Investment Advisors LLC Purchases 211 Shares of Amgen Inc. (NASDAQ:AMGN)

BHK Investment Advisors LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 9.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,459 shares of the medical research company’s stock after purchasing an additional 211 shares during the quarter. BHK Investment Advisors LLC’s holdings in Amgen were worth $641,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Capital Performance Advisors LLP acquired a new position in shares of Amgen during the third quarter valued at about $25,000. Legacy Investment Solutions LLC bought a new position in Amgen in the 3rd quarter valued at about $29,000. Centricity Wealth Management LLC acquired a new position in Amgen during the 4th quarter valued at about $25,000. Heck Capital Advisors LLC bought a new stake in Amgen during the 4th quarter worth approximately $36,000. Finally, Kennebec Savings Bank purchased a new stake in shares of Amgen in the third quarter worth approximately $57,000. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 2.2 %

Shares of AMGN opened at $309.72 on Tuesday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market cap of $166.38 billion, a PE ratio of 41.02, a P/E/G ratio of 2.63 and a beta of 0.56. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The business’s 50-day moving average price is $277.14 and its 200-day moving average price is $300.20.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.07%. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is 126.09%.

Insiders Place Their Bets

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 in the last ninety days. 0.69% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several analyst reports. Truist Financial cut their target price on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday, January 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 target price on shares of Amgen in a research note on Tuesday, November 12th. Bank of America raised their price target on shares of Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a research report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Finally, Piper Sandler increased their price target on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $314.09.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.